Renal protective effect of troglitazone in Wistar fatty rats

K. Fujiwara, K. Hayashi, Y. Ozawa, Hirobumi Tokuyama, A. Nakamura, T. Saruta

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Although it is known that renal injury develops in obesity and diabetes mellitus, there have been no investigations examining the impact of insulin resistance per se on the development of renal injury. The present study was undertaken to examine whether insulin resistance and obesity influence urinary protein excretion (UPE) in female heminephrectomized Wistar fatty rats (WFRs). After 24 weeks of heminephrectomy in WFRs, the body weight ([BW], 465 ± 18 g; n = 6), blood pressure (155 ± 5 mm Hg), serum insulin to glucose ratio (1.31 ± 0.39 μU/mg), and daily UPE (24 ± 7 mg/d) were greater versus Wistar lean rats ([WLRs] 258 ± 8 g, 134 ± 1 mm Hg, 0.19 ± 0.06 μU/mg, and 5 ± 1 mg/d, respectively; n = 6), whereas blood glucose levels did not increase significantly. In WFRs, long-term (ie, 24 weeks) treatment with troglitazone, an insulin-sensitizing agent, improved the serum insulin to glucose ratio (0.17 ± 0.09 μU/mg), reduced blood pressure (to 140 ± 4 mm Hg), and decreased UPE (to 7 ± 1 mg/d), although it had no effect on BW. Of note, with troglitazone treatment, the reduction in proteinuria preceded the correction of hypertension (ie, at week 12). In conclusion, our study suggests that insulin resistance per se causes proteinuria that does not appear to depend on blood pressure. Furthermore, long-term therapy with troglitazone may be a useful tool for the treatment of renal injury in the insulin-resistant condition. Copyright (C) 2000 by W.B. Saunders Company.

Original languageEnglish
Pages (from-to)1361-1364
Number of pages4
JournalMetabolism: Clinical and Experimental
Volume49
Issue number10
DOIs
Publication statusPublished - 2000

Fingerprint

troglitazone
Wistar Rats
Insulin
Kidney
Insulin Resistance
Blood Pressure
Proteinuria
Wounds and Injuries
Obesity
Body Weight
Glucose
Proteins
Nephrectomy
Serum
Blood Glucose
Diabetes Mellitus
Hypertension

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Renal protective effect of troglitazone in Wistar fatty rats. / Fujiwara, K.; Hayashi, K.; Ozawa, Y.; Tokuyama, Hirobumi; Nakamura, A.; Saruta, T.

In: Metabolism: Clinical and Experimental, Vol. 49, No. 10, 2000, p. 1361-1364.

Research output: Contribution to journalArticle

Fujiwara, K, Hayashi, K, Ozawa, Y, Tokuyama, H, Nakamura, A & Saruta, T 2000, 'Renal protective effect of troglitazone in Wistar fatty rats', Metabolism: Clinical and Experimental, vol. 49, no. 10, pp. 1361-1364. https://doi.org/10.1053/meta.2000.9509
Fujiwara, K. ; Hayashi, K. ; Ozawa, Y. ; Tokuyama, Hirobumi ; Nakamura, A. ; Saruta, T. / Renal protective effect of troglitazone in Wistar fatty rats. In: Metabolism: Clinical and Experimental. 2000 ; Vol. 49, No. 10. pp. 1361-1364.
@article{7282fa57558e4a61832138c172d6a85b,
title = "Renal protective effect of troglitazone in Wistar fatty rats",
abstract = "Although it is known that renal injury develops in obesity and diabetes mellitus, there have been no investigations examining the impact of insulin resistance per se on the development of renal injury. The present study was undertaken to examine whether insulin resistance and obesity influence urinary protein excretion (UPE) in female heminephrectomized Wistar fatty rats (WFRs). After 24 weeks of heminephrectomy in WFRs, the body weight ([BW], 465 ± 18 g; n = 6), blood pressure (155 ± 5 mm Hg), serum insulin to glucose ratio (1.31 ± 0.39 μU/mg), and daily UPE (24 ± 7 mg/d) were greater versus Wistar lean rats ([WLRs] 258 ± 8 g, 134 ± 1 mm Hg, 0.19 ± 0.06 μU/mg, and 5 ± 1 mg/d, respectively; n = 6), whereas blood glucose levels did not increase significantly. In WFRs, long-term (ie, 24 weeks) treatment with troglitazone, an insulin-sensitizing agent, improved the serum insulin to glucose ratio (0.17 ± 0.09 μU/mg), reduced blood pressure (to 140 ± 4 mm Hg), and decreased UPE (to 7 ± 1 mg/d), although it had no effect on BW. Of note, with troglitazone treatment, the reduction in proteinuria preceded the correction of hypertension (ie, at week 12). In conclusion, our study suggests that insulin resistance per se causes proteinuria that does not appear to depend on blood pressure. Furthermore, long-term therapy with troglitazone may be a useful tool for the treatment of renal injury in the insulin-resistant condition. Copyright (C) 2000 by W.B. Saunders Company.",
author = "K. Fujiwara and K. Hayashi and Y. Ozawa and Hirobumi Tokuyama and A. Nakamura and T. Saruta",
year = "2000",
doi = "10.1053/meta.2000.9509",
language = "English",
volume = "49",
pages = "1361--1364",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Renal protective effect of troglitazone in Wistar fatty rats

AU - Fujiwara, K.

AU - Hayashi, K.

AU - Ozawa, Y.

AU - Tokuyama, Hirobumi

AU - Nakamura, A.

AU - Saruta, T.

PY - 2000

Y1 - 2000

N2 - Although it is known that renal injury develops in obesity and diabetes mellitus, there have been no investigations examining the impact of insulin resistance per se on the development of renal injury. The present study was undertaken to examine whether insulin resistance and obesity influence urinary protein excretion (UPE) in female heminephrectomized Wistar fatty rats (WFRs). After 24 weeks of heminephrectomy in WFRs, the body weight ([BW], 465 ± 18 g; n = 6), blood pressure (155 ± 5 mm Hg), serum insulin to glucose ratio (1.31 ± 0.39 μU/mg), and daily UPE (24 ± 7 mg/d) were greater versus Wistar lean rats ([WLRs] 258 ± 8 g, 134 ± 1 mm Hg, 0.19 ± 0.06 μU/mg, and 5 ± 1 mg/d, respectively; n = 6), whereas blood glucose levels did not increase significantly. In WFRs, long-term (ie, 24 weeks) treatment with troglitazone, an insulin-sensitizing agent, improved the serum insulin to glucose ratio (0.17 ± 0.09 μU/mg), reduced blood pressure (to 140 ± 4 mm Hg), and decreased UPE (to 7 ± 1 mg/d), although it had no effect on BW. Of note, with troglitazone treatment, the reduction in proteinuria preceded the correction of hypertension (ie, at week 12). In conclusion, our study suggests that insulin resistance per se causes proteinuria that does not appear to depend on blood pressure. Furthermore, long-term therapy with troglitazone may be a useful tool for the treatment of renal injury in the insulin-resistant condition. Copyright (C) 2000 by W.B. Saunders Company.

AB - Although it is known that renal injury develops in obesity and diabetes mellitus, there have been no investigations examining the impact of insulin resistance per se on the development of renal injury. The present study was undertaken to examine whether insulin resistance and obesity influence urinary protein excretion (UPE) in female heminephrectomized Wistar fatty rats (WFRs). After 24 weeks of heminephrectomy in WFRs, the body weight ([BW], 465 ± 18 g; n = 6), blood pressure (155 ± 5 mm Hg), serum insulin to glucose ratio (1.31 ± 0.39 μU/mg), and daily UPE (24 ± 7 mg/d) were greater versus Wistar lean rats ([WLRs] 258 ± 8 g, 134 ± 1 mm Hg, 0.19 ± 0.06 μU/mg, and 5 ± 1 mg/d, respectively; n = 6), whereas blood glucose levels did not increase significantly. In WFRs, long-term (ie, 24 weeks) treatment with troglitazone, an insulin-sensitizing agent, improved the serum insulin to glucose ratio (0.17 ± 0.09 μU/mg), reduced blood pressure (to 140 ± 4 mm Hg), and decreased UPE (to 7 ± 1 mg/d), although it had no effect on BW. Of note, with troglitazone treatment, the reduction in proteinuria preceded the correction of hypertension (ie, at week 12). In conclusion, our study suggests that insulin resistance per se causes proteinuria that does not appear to depend on blood pressure. Furthermore, long-term therapy with troglitazone may be a useful tool for the treatment of renal injury in the insulin-resistant condition. Copyright (C) 2000 by W.B. Saunders Company.

UR - http://www.scopus.com/inward/record.url?scp=0033783898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033783898&partnerID=8YFLogxK

U2 - 10.1053/meta.2000.9509

DO - 10.1053/meta.2000.9509

M3 - Article

VL - 49

SP - 1361

EP - 1364

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 10

ER -